|
Re: Received a response....Third Eye Loan Balance-Updated
|
2
|
Resverlogix Corp.
|
Jul 16, 2019 12:43PM
|
|
Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....
|
4
|
Resverlogix Corp.
|
Mar 23, 2020 02:28PM
|
|
Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....
|
2
|
Resverlogix Corp.
|
Mar 23, 2020 05:48PM
|
|
Re: Recent publications:
|
3
|
Resverlogix Corp.
|
Sep 27, 2023 03:28PM
|
|
Re: ReCvr
|
2
|
Resverlogix Corp.
|
Sep 25, 2017 02:58PM
|
|
Re: Remembering Relypsa
|
6
|
Resverlogix Corp.
|
Nov 30, 2018 02:34AM
|
|
Re: Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
|
3
|
Resverlogix Corp.
|
Dec 05, 2019 08:47PM
|
|
Re: Renal and Fabry trial listings updated on ClinicalTrials.gov
|
5
|
Resverlogix Corp.
|
Apr 21, 2018 04:32PM
|
|
Re: Renal trial delayed (again)
|
4
|
Resverlogix Corp.
|
Sep 28, 2017 02:21AM
|
|
Re: Renal trial delayed (again)
|
4
|
Resverlogix Corp.
|
Sep 28, 2017 11:13AM
|
|
Re: Report of exempt distribution
|
1
|
Resverlogix Corp.
|
Nov 11, 2020 01:15AM
|
|
Re: Report of exempt distribution
|
2
|
Resverlogix Corp.
|
Nov 10, 2020 05:27PM
|
|
Re: Report Of Exempt Distribution.
|
2
|
Zenith Epigenetics
|
Apr 18, 2024 12:30AM
|
|
Re: Response from Sarah -were still a go
|
2
|
Resverlogix Corp.
|
Dec 02, 2021 04:54PM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
8
|
Resverlogix Corp.
|
Aug 15, 2017 03:58PM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
3
|
Resverlogix Corp.
|
Aug 15, 2017 10:11AM
|
|
Re: RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT
|
4
|
Resverlogix Corp.
|
Jan 08, 2018 05:18PM
|
|
Re: RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT
|
5
|
Resverlogix Corp.
|
Jan 10, 2018 12:31AM
|
|
Re: Resverlogix and the Toronto Maple Leafs.....
|
2
|
Resverlogix Corp.
|
Apr 24, 2017 01:14AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
6
|
Resverlogix Corp.
|
Aug 29, 2023 01:39PM
|
